跳转至内容
Merck
CN

主要文件

查看所有文档

SML2111

GSK8814

≥98% (HPLC)

别名:

8-((3R,4R,5S)-3-((4,4-Difluorocyclohexyl)methoxy)-5-methoxypiperidin-4-ylamino)-3-methyl-5-(5-methylpyridin-3-yl)-1,7-naphthyridin-2(1H)-one, 8-[[(3R,4R,5S)-3-[(4,4-Difluorocyclohexyl)methoxy]-5-methoxy-4-piperidinyl]amino]-3-methyl-5-(5-methyl-3-pyridinyl)-1,7-naphthyridin-2(1H)-one

登录 查看组织和合同定价。

选择规格

变更视图

关于此项目

经验公式（希尔记法）:
C28H35F2N5O3
化学文摘社编号:
1997369-78-4
分子量:
527.61
UNSPSC Code:
51111800
NACRES:
NA.77
Assay:
≥98% (HPLC)
Form:
powder
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

assay

≥98% (HPLC)

form

powder

color

colorless to very dark brown

solubility

DMSO: 2 mg/mL, clear

storage temp.

−20°C

SMILES string

O=C(N1)C(C)=CC2=C1C(N[C@H]3[C@H](OCC4CCC(F)(F)CC4)CNC[C@@H]3OC)=NC=C2C5=CN=CC(C)=C5

Biochem/physiol Actions

Aqueous soluble inhibitor that targets ATAD2 & ATAD2B bromodomain with high selectivity and submicromolar affinity.
GSK8814 is an aqueous soluble (>439 μM) inhibitor that targets ATAD2 & ATAD2B bromodomain (BD) with submicromolar affinity (pKd = 8.1 for ATAD2 by ITC) and high selectivity (pIC50 = 7.3/ATAD2 BD & 7.7/ATAD2B BD in competitive ligand binding assays by TR-FRET; pIC50 ≤4.5 when using BD1/BD2 of BRD2-4 or BRDT). When tested using intact cells, GSK8814 effectively disrupts histone H3.3 interaction with ATAD2 BD construct (IC50 = 2.7 μM), but not full-length ATAD2. GSK8814, but not its less active diastereomer GSK8815, is shown to suppress LNCaP colony formation in a soft agar assay, albeit with a high effective concentration (by 56% at 20 μM).

存储类别

11 - Combustible Solids

wgk

WGK 3

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系 客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库